Opinion

Video

Impact of Comorbidities on IPF Management

Author(s):

Toby Maher, MD, PhD

Key Takeaways

  • Comorbidities can obscure IPF symptoms, leading to diagnostic delays or misdiagnoses, complicating the clinical presentation.
  • Comprehensive evaluation is crucial to tailor treatment plans addressing both IPF and comorbidities effectively.
SHOW MORE

Toby Maher, MD, PhD, discusses how comorbidities complicate the diagnosis and management of idiopathic pulmonary fibrosis (IPF) and influence treatment decisions, highlighting the need for a comprehensive approach in patient care.

Video content above is prompted by the following:

How do comorbidities affect diagnosis and management of IPF? In what ways do comorbidities affect treatment decisions?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr John Mascarenhas
5 experts are featured in this series
2 experts in this video
4 experts in this video
5 experts are featured in this series
4 experts in this video
1 expert is featured in this series.
Related Content
Ovarian cancer | Image Credit: tashatuvango - stock.adobe.com
June 27th 2025

Final PICCOLO Data Highlight Efficacy of Mirvetuximab Soravtansine in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

Kristi Rosa
Mirvetuximab soravtansine continues to show efficacy and safety in the final analysis of the phase 2 PICCOLO study.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Doctor looking at lung imaging | Image credit: shidlovski – stock.adobe.com
June 26th 2025

Deep Learning Biomarkers Help Uncover ENV-101 Treatment Effects in IPF

Hayden E. Klein
At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those receiving placebo.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
3D illustration of ovarian cancer | Image Credit: Dr_Microbe - stock.adobe.com
June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan
Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.
Marginal zone lymphoma | Image: Atlas of Hematological Cytology
June 24th 2025

In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel

Mary Caffrey
In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo